How Common and How Severe? Adenovirus Infection after PTCy-Based GVHD Prophylaxis

The ASTCT Transplant Infectious Diseases SIG April 2026 Journal Club will air on Wednesday, April 22 at 12 p.m. CT/1 p.m. ET. The webinar consists of a 40-minute journal club presentation and 20 minutes for discussion and a Q & A session. In the April Journal Club session, Dr. Fernando Gibran L. Nunes will present Incidence and Outcomes of Adenovirus Infections after Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

Session Description:

Adenovirus remains an important infectious complication following allogeneic hematopoietic cell transplantation, particularly in the setting of evolving graft-versus-host disease prophylaxis strategies. This journal club will review a contemporary study evaluating the incidence, timing, and clinical outcomes of adenovirus infection in patients receiving post-transplant cyclophosphamide (PTCy)-based prophylaxis. Through critical appraisal of the data, participants will explore the clinical significance of adenovirus detection, risk factors for progression to disease, and the impact on transplant outcomes. The session will also address practical considerations for surveillance and management in the modern transplant era, with a focus on implications for adult transplant practice.

Presenters & Articles:

Fernando Gibran L. Nunes, MD.

Hospital Sirio Libanês in São Paulo, Brazil

Article: Incidence and Outcomes of Adenovirus Infections after Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

Moderators:

Diego R. Hijano, MD, MSc

St. Jude Children's Research Hospital in Chicago, Illinois

Zainab Shahid, MD, FACP, FIDSA

Memorial Sloan Kettering Cancer Center in New York City, NY

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Describe the incidence and timing of adenovirus infection following allogeneic hematopoietic cell transplant with PTCy-based GVHD prophylaxis.
• Evaluate the clinical outcomes associated with adenovirus infection, including progression to disease and impact on mortality.
• Discuss implications for surveillance, risk stratification, and management of adenovirus in the modern PTCy transplant setting.

The American Society for Transplantation and Cellular Therapy (ASTCT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The American Society for Transplantation and Cellular Therapy (ASTCT) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Name: Diego Hijano, MD, MSc

Role: Moderator

Company: Pfizer

Nature of Relationship: Consultant; consulting fees

The American Society for Transplantation and Cellular Therapy (ASTCT) has reviewed all relevant financial relationships disclosed by planners, faculty, and others in control of educational content. All identified conflicts of interest were mitigated prior to the educational activity through appropriate ACCME-compliant strategies to ensure independence, objectivity, and scientific rigor.